(Q45185252)

10 December 2017

title

Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis (English)

1 reference

10 December 2017

main subject

visceral leishmaniasis

1 reference

Anny Fortin

1

1 reference

10 December 2017

Sarah Hendrickx

2

1 reference

10 December 2017

Vanessa Yardley

3

1 reference

10 December 2017

Paul Cos

4

1 reference

10 December 2017

Herwig Jansen

5

1 reference

10 December 2017

Louis Maes

6

1 reference

10 December 2017

language of work or name

English

0 references

publication date

10 July 2012

1 reference

Journal of Antimicrobial Chemotherapy

10 December 2017

published in

1 reference

10 December 2017

volume

67

1 reference

10 December 2017

issue

11

1 reference

10 December 2017

page(s)

2707-2712

1 reference

The increase in risk factors for leishmaniasis worldwide

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Drug resistance in Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Drug resistance in leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Ether lipids and derivatives as investigational anticancer drugs. A brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Development of miltefosine as an oral treatment for leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Drug combinations for visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

In vitro and in vivo anti-leishmanial activity of triterpenoid saponins isolated from Maesa balansae and some chemical derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Miltefosine: issues to be addressed in the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

A policy for leishmaniasis with respect to the prevention and control of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Developments in the treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Treatment of leishmaniasis with miltefosine: 2008 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Drug delivery strategies for therapy of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

Leishmania resistance to miltefosine associated with genetic marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS273

21 January 2018

Identifiers

DOI

10.1093/JAC/DKS273

1 reference

10 December 2017

1 reference